Chadwick Terrence King

Title: Chadwick Terrence King: Innovator in Monoclonal Antibodies

Introduction

Chadwick Terrence King is a notable inventor based in Vancouver, Canada. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work focuses on addressing critical health issues, including hypercholesterolemia.

Latest Patents

Chadwick holds a patent for "Monoclonal antibodies to proprotein convertase subtilisin kexin type 9 (PCSK9)." This patent describes antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9). The methods outlined in the patent include treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9. Additionally, the patent details methods for detecting the amount of PCSK9 in a sample using these antigen binding proteins.

Career Highlights

Chadwick is currently associated with Amgen Inc., a leading biotechnology company. His work at Amgen has allowed him to contribute to innovative solutions in the medical field. With a focus on developing therapies that can significantly impact patient health, he continues to push the boundaries of scientific research.

Collaborations

Chadwick collaborates with esteemed colleagues, including Simon Mark Jackson and Nigel Pelham Clinton Walker. These partnerships enhance the research and development efforts within his field, fostering innovation and progress.

Conclusion

Chadwick Terrence King is a prominent figure in the biotechnology sector, recognized for his innovative work on monoclonal antibodies. His contributions have the potential to transform treatment options for various disorders, showcasing the importance of research and collaboration in advancing medical science.